Talabostat Plus Pembrolizumab Exhibits Activity in mCRPC With SCNC Phenotype
Combination talabostat and pembrolizumab has shown antitumor activity in patients who have metastatic castration-resistant prostate cancer with small-cell neuroendocrine carcinoma phenotype.